Silymarin Inhibits Cell Cycle Progression and mTOR Activity in Activated Human T Cells: Therapeutic Implications for Autoimmune Diseases

Basic and Clinical Pharmacology and Toxicology

Volumn 112, Issue 4, 2013, Pages 251-256

  Gharagozloo, Marjan ^a   Javid, Elahe N ^a   Rezaei, Abbas ^a   Mousavizadeh, Kazem ^b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD3 ANTIBODY; DIMETHYL SULFOXIDE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SILYMARIN;

ARTICLE; AUTOIMMUNE DISEASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL ISOLATION; CELL LYSATE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOMODULATION; INCUBATION TIME; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STAINING; T LYMPHOCYTE; TREATMENT INDICATION;

AUTOIMMUNE DISEASES; CELL CYCLE; CELL PROLIFERATION; DIMETHYL SULFOXIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; IMMUNOLOGIC FACTORS; LEUKOCYTES, MONONUCLEAR; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SILYMARIN; T-LYMPHOCYTES; TIME FACTORS; TOR SERINE-THREONINE KINASES;

SILYBUM MARIANUM;

EID: 84875063931     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12032     Document Type: Article

References (26)

1. Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009;9:324-37.
2. Weichhart T, Säemann MD. The multiple facets of mTOR in immunity. Trends Immunol 2009;30:218-26.
3. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926-45.
4. Reif K, Burgering BM, Cantrell DA. Phosphatidylinositol 3-kinase links the interleukin-2 receptor to protein kinase B and p70 S6 kinase. J Biol Chem 1997;272:14426-33.
5. Ponticelli C. Present and future of immunosuppressive therapy in kidney transplantation. Transplant Proc 2011;43:2439-40.
6. Tsang CK, Qi H, Liu LF, Zheng XF. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today 2007;12:112-24.
7. Kurtz JE, Ray-Coquard I. PI3 Kinase Inhibitors in the Clinic: an Update. Anticancer Res 2012;32:2463-70.
8. Gazák R, Walterová D, Kren V. Silybin and silymarin-new and emerging applications in medicine. Curr Med Chem 2007;14:315-38.
9. Gharagozloo M, Velardi E, Bruscoli S, Agostini M, Di Sante M, Donato V et al. Silymarin suppress CD4 + T cell activation and proliferation: effects on NF-kappaB activity and IL-2 production. Pharmacol Res 2010;61:405-9.
10. Schümann J, Prockl J, Kiemer AK, Vollmar AM, Bang R, Tiegs G. Silibinin protects mice from T cell-dependent liver injury. J Hepatol 2003;39:333-40.
11. Meroni PL, Barcellini W, Borghi MO, Vismara A, Ferraro G, Ciani D et al. Silybin inhibition of human T-lymphocyte activation. Int J Tissue React 1988;10:177-81.
12. Morishima C, Shuhart MC, Wang CC, Paschal DM, Apodaca MC, Liu Y et al. Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection. Gastroenterology 2010;138:671-81.
13. Zhang Q, Kelly AP, Wang L, French SW, Tang X, Duong HS et al. Green tea extract and (-)-epigallocatechin-3-gallate inhibit mast cell-stimulated type I collagen expression in keloid fibroblasts via blocking PI-3K/AkT signaling pathways. J Invest Dermatol 2006;126:2607-13.
14. Liu M, Liu F. Resveratrol inhibits mTOR signaling by targeting DEPTOR. Commun Integr Biol 2011;4:382-4.
15. Liu M, Wilk SA, Wang A, Zhou L, Wang RH, Ogawa W et al. Resveratrol inhibits mTOR signaling by promoting the interaction between mTOR and DEPTOR. J Biol Chem 2010;285:36387-94.
16. Beevers CS, Chen L, Liu L, Luo Y, Webster NJ, Huang S. Curcumin disrupts the Mammalian target of rapamycin-raptor complex. Cancer Res 2009;69:1000-8.
17. Wang JY, Chang CC, Chiang CC, Chen WM, Hung SC. Silibinin suppresses the maintenance of colorectal cancer stem-like cells by inhibiting PP2A/AKT/mTOR pathways. J Cell Biochem 2012;113:1733-43.
18. García-Maceira P, Mateo J. Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy. Oncogene 2009;28:313-24.
19. Favero J, Lafont V. Effector pathways regulating T cell activation. Biochem Pharmacol 1998;56:1539-47.
20. Gharagozloo M, Amirghofran Z. Effects of silymarin on the spontaneous proliferation and cell cycle of human peripheral blood leukemia T cells. J Cancer Res Clin Oncol 2007;133:525-32.
21. Terada N, Takase K, Papst P, Nairn AC, Gelfand EW. Rapamycin inhibits ribosomal protein synthesis and induces G1 prolongation in mitogen-activated T lymphocytes. J Immunol 1995;155:3418-26.
22. Dieterlen MT, Bittner HB, Klein S, von Salisch S, Mittag A, Tárnok A et al. Assay validation of phosphorylated S6 ribosomal protein for a pharmacodynamic monitoring of mTOR-inhibitors in peripheral human blood. Cytometry B Clin Cytom 2012;82:151-7.
23. Fernandez D, Bonilla E, Mirza N, Niland B, Perl A. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:2983-8.
24. Monti P, Scirpoli M, Maffi P, Piemonti L, Secchi A, Bonifacio E et al. Rapamycin monotherapy in patients with type 1 diabetes modifies CD4 + CD25 + FOXP3 + regulatory T-cells. Diabetes 2008;57:2341-7.
25. Min K, Yoon WK, Kim SK, Kim BH. Immunosuppressive effect of silibinin in experimental autoimmune encephalomyelitis. Arch Pharm Res 2007;30:1265-72.
26. Esposito M, Ruffini F, Bellone M, Gagliani N, Battaglia M, Martino G et al. Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation. J Neuroimmunol 2010;220:52-63.